Add-on Acquisition • Life Science

Zymeworks Acquires Kairos Therapeutics

On March 22, 2016, Zymeworks acquired life science company Kairos Therapeutics

Acquisition Context

This is Zymeworks’ 1st transaction in the Life Science sector.
This is Zymeworks’ 1st transaction in Canada.
This is Zymeworks’ 1st transaction in British Columbia.

Explore All 3109 Add-on Acquisition Life Science Deals - Search the Database Free

M&A Deal Summary
Date	March 22, 2016
Target	Kairos Therapeutics
Sector	Life Science
Buyer(s)	Zymeworks
Deal Type	Add-on Acquisition

Target Company

Kairos Therapeutics

Vancouver, British Columbia, Canada

Kairos Therapeutics, Inc. is a bio pharmaceutical company specialists in the discovery and development of antibody drug conjugates (ADCs), spun out of The Centre for Drug Research and Development (CDRD).

Explore More Deals

Browse All 215,156 Deals

FILTER BY

Buyer Type (PE or Strategic)
Deal Size ($10M to $10B+)
Sector (60 Sectors)
Deal Type
Geography
& More

Search Free

Buyer Overview 1

Buyer

Zymeworks

Vancouver, British Columbia, Canada

Category	Company
Founded	2003
Sector	Life Science

DESCRIPTION

Zymeworks, Inc. is a biotherapeutics company that is developing best-in-class Azymetric™ bi-specific antibodies and antibody drug conjugates for the treatment of cancer, autoimmune and inflammatory diseases.

Deal Context for Buyer	#
Overall	1 of 1
Sector: Life Science	1 of 1
Type: Add-on Acquisition	1 of 1
State: British Columbia	1 of 1
Country: Canada	1 of 1
Year: 2016	1 of 1

Explore Related M&A Activity

Life Science M&A - Add-on Acquisition M&A Deals - British Columbia M&A - Canada M&A - 2016 M&A